SION
NASDAQSionna Therapeutics Inc.
Price$32.57-1.33 (-3.92%)
02:00 PM06:15 PM
News · 26 weeks44-64%
2025-12-142026-06-07
Mix2290d
- Insider8(36%)
- Other7(32%)
- SEC Filings6(27%)
- Analyst1(5%)
Latest news
25 items- SECAmendment: SEC Form 144/A filed by Sionna Therapeutics Inc.144/A - Sionna Therapeutics, Inc. (0002036042) (Subject)
- INSIDERDirector Thompson Peter A. sold $4,493 worth of shares (101 units at $44.49) as part of a pre-agreed trading plan (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERDirector Orbimed Advisors Llc sold $4,493 worth of shares (101 units at $44.49) as part of a pre-agreed trading plan (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- SECSEC Form 144 filed by Sionna Therapeutics Inc.144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
- PRSionna Therapeutics to Participate in Upcoming June 2026 Investor ConferencesWALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events: 2026 Jefferies Global Healthcare Conference presentation on Wednesday, June 3rd, 2026, at 12:15 p.m. ET; andGoldman Sachs 47th Annual Global Healthcare Conference 2026 fireside chat on Wednesday, June 10th, 2026, at 10:00 a.m. ET Live webcasts can be accessed in the ‘Investors' section of Sionna's website at https://investors.sionnatx.com. Replays will also be available following t
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sionna Therapeutics Inc.SCHEDULE 13G/A - Sionna Therapeutics, Inc. (0002036042) (Subject)
- PRSionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceWALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET. A live webcast can be accessed in the ‘Investors' section of Sionna's website at https://investors.sionnatx.com/. A replay will also be available following the event. About Sionna Therapeutics Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sionna Therapeutics Inc.SCHEDULE 13G/A - Sionna Therapeutics, Inc. (0002036042) (Subject)
- SECSEC Form 10-Q filed by Sionna Therapeutics Inc.10-Q - Sionna Therapeutics, Inc. (0002036042) (Filer)
- SECSionna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Sionna Therapeutics, Inc. (0002036042) (Filer)
- INSIDERDirector Thompson Peter A. sold $13,364,064 worth of shares (292,952 units at $45.62) as part of a pre-agreed trading plan (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERDirector Orbimed Advisors Llc sold $13,364,064 worth of shares (292,952 units at $45.62) as part of a pre-agreed trading plan (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- ANALYSTWedbush initiated coverage on Sionna Therapeutics with a new price targetWedbush initiated coverage of Sionna Therapeutics with a rating of Outperform and set a new price target of $53.00
- SECSEC Form DEFA14A filed by Sionna Therapeutics Inc.DEFA14A - Sionna Therapeutics, Inc. (0002036042) (Filer)
- SECSEC Form DEF 14A filed by Sionna Therapeutics Inc.DEF 14A - Sionna Therapeutics, Inc. (0002036042) (Filer)
- PRSionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic FibrosisWALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced the completion of enrollment in the PreciSION CF Phase 2a proof-of-concept (POC) trial. This trial is evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when added to Trikafta® (elexacaftor/tezacaftor/ivacaftor), the current standard of care (SOC) in CF. Sionna anticipates data from the PreciSION CF trial in the summer of 2026. "Completion of enrollment in our PreciSION CF proof-of-concept trial represents a significant m
- INSIDERSEC Form 4 filed by Thompson Peter A.4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Orbimed Advisors Llc4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Sionna Therapeutics Inc.SCHEDULE 13D/A - Sionna Therapeutics, Inc. (0002036042) (Subject)
- INSIDERSEC Form 4 filed by Thompson Peter A.4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Orbimed Advisors Llc4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- PRSionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation SymposiumWALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14th, 2026. About Sionna Therapeutics Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF)
- INSIDERChief Legal Officer Fitzpatrick Jennifer exercised 10,250 shares at a strike of $6.11 and sold $347,019 worth of shares (10,250 units at $33.86) (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- SECSEC Form S-8 filed by Sionna Therapeutics Inc.S-8 - Sionna Therapeutics, Inc. (0002036042) (Filer)
- SECSEC Form S-3ASR filed by Sionna Therapeutics Inc.S-3ASR - Sionna Therapeutics, Inc. (0002036042) (Filer)
SION FAQ
6 questionsWhere does SION stock trade?
Sionna Therapeutics Inc. (SION) is listed on NASDAQ.What sector and industry is SION in?
Sionna Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Sionna Therapeutics Inc. go public?
Sionna Therapeutics Inc. (SION) completed its IPO in 2025.What are analysts saying about SION?
Sionna Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wedbush: Outperform on 2026-05-05. Recent price targets range from $2200.00 to $4500.00.What companies are similar to SION?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SION side-by-side with any of them on Quantisnow.How can I track SION on Quantisnow?
Quantisnow aggregates Sionna Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SION to receive live email and push alerts on every new disclosure.